Innovation Zed Announce 2022 Launch of InsulCheck DOSE Add-on Technology for Insulin Pens

Innovation Zed Announce 2022 Launch of InsulCheck DOSE Add-on Technology for Insulin Pens

Dublin, Ireland November 15, 2021

Innovation Zed, developer of novel diabetes management technologies (the InsulCheck range), headquartered at NovaUCD, at University College Dublin, Ireland are delighted to announce today the arrival of the much anticipated InsulCheck DOSE technology that will be coming to market in 2022.

“It is with great excitement that we announce the arrival of our InsulCheck DOSE by Innovation Zed. As the third generation product of the InsulCheck family, this technology has been a dream of our company from its very inception and this product is the culmination of over a decade of work to support multiple daily injection (MDI) pen users. We understood the difficult challenges presented by various injection pens and in particular the difficulties in working on a technology to reliably and accurately support low-cost disposable pens. This is the reason we at Innovation Zed took an incremental approach to developing the InsulCheck DOSE product.” – said Dr Dean Minnock, CEO at Innovation Zed. “We have taken a unique approach in developing this technology by working closely with users, caregivers, software developers, medical device specialists and previous generations of InsulCheck products to design and develop a product that bolsters and supports the needs of all stakeholders” – he continued.

Innovation Zed has collaborated with SHL Medical in the development of InsulCheck DOSE. SHL Medical is a world-leading provider of drug delivery solutions and also offers design-to-build and contract manufacturing services for various medical products through its subsidiary, SHL Technologies.

WHAT IS INSULCHECK DOSE?

InsulCheck DOSE is a single unit add-on device for pen injectors that automatically captures dose value dialled, injection event time stamp, temperature and mounting/unmounting events. Through Bluetooth® Low Energy (BLE) technology, InsulCheck DOSE transmits these data points to a paired companion software platform in real time for inclusion in diabetes management therapy.

“InsulCheck DOSE technology supports MDI users by enhancing their traditional injection pen and transforming it into a smart pen that can optimise their treatment and reduce the stresses caused by MDI therapy. Through this technology we are enabling every MDI user to make their existing injection pen a smart pen without having to compromise or change from their existing HMO or health service provider” – said Dr Minnock.

INSULCHECK DOSE FEATURES

The technology utilises a multi-sensor approach to accurately detect and register the actual dosage dialled and provide an injection event time stamp to log the event. The incorporated temperature sensors constantly monitor the ambient temperature of the area surrounding the injection pen, providing safety notifications to the user if the surrounding temperature may affect the drug housed inside the pen. Using an OLED display, InsulCheck DOSE provides visual information and feedback to the user, helping improve best practice procedures. A rechargeable lithium battery powers the DOSE device and is capable of operating well over 1 week at a time between charges. As a BLE enabled product, all data captured by InsulCheck DOSE is transferred in real time to a paired mobile application. If the user does not wish or is unable to remain connected with a companion software platform, InsulCheck DOSE has built-in memory to store over 40 days’ worth of injection history at a time. Through modification of the sleeve component and firmware refinement, InsulCheck DOSE can become applicable to all injection pens for various drug treatments. At launch, it will support a range of reusable and disposable injection pens on the insulin market from Novo Nordisk, Lilly and Sanofi.

“Our ability to learn, adapt and improve our technology is one of the key aspects of InsulCheck DOSE and one that separates us greatly from our competitors. The future-proof design of InsulCheck DOSE means that it can be adapted to support the various pen mechanisms in use today, whilst maintaining accuracy and reliability for the patient. Among the numerous unique features of this product is the built in Firmware Over The Air (FOTA) capability which allows continuous optimisation of the device’s firmware even when deployed in the field. That future-proofing allows InsulCheck DOSE to adapt to physical injection pen variations from the pen manufacturers and improve on device performance ‘on the go’ from real world user behaviours” – said Dr Minnock.

VALUE PROPOSITION

The InsulCheck DOSE device helps patients, automatically track their daily injection and monitor treatment adherence. The intended use of InsulCheck DOSE is as a supporting component in a management ecosystem for therapy optimisation, remote monitoring and enhanced connected care. Dr Minnock explained,

“InsulCheck DOSE is a disruptive technology that will revolutionise an entire market and change the lives of millions of MDI users worldwide. Innovation Zed have entered into discussions with market leaders in the diabetes management sector with the intention of finding a strategic global partner in taking this InsulCheck DOSE technology to the market. InsulCheck DOSE is an attractive offering to any organisation working in this space as it can significantly enhance their existing offering to become more competitive and command new growth and additional market share.”

CONCLUSION

InsulCheck DOSE enters production at the end of Q2 2022 and will be available as an FDA registered and CE marked product. Manufacturing of InsulCheck DOSE will be handled by Innovation Zed’s existing manufacturing partner SHL Technologies, a subsidiary of SHL Medical. If you wish to understand InsulCheck DOSE or any of our technology offerings in greater detail, please feel free to visit our website or reach out to us directly.


The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Innovation Zed is under license. Other trademarks and trade names are those of their respective owners.


Innovation Zed Announce Non-Invasive CGM Project and New Researcher

Innovation Zed Announce Non-Invasive Continuous Glucose Monitoring Project and Appointment of a New Researcher

Dublin, Ireland October 11, 2021

Innovation Zed Ltd., developer of novel diabetes technologies (the InsulCheck range), announced further advancement in their research of technologies for non-invasive Continuous Glucose Monitoring and a new researcher to this project, Dr Rui Wu.

Innovation Zed, headquartered at NovaUCD, the Centre for New Ventures and Entrepreneurs at University College Dublin, who develop technologies to improve the health and quality of life for individuals living with diabetes, has taken another leap forward in the development of a non-invasive glucometer.

Innovation Zed has collaborated with the Irish Research Council (IRC) and University College Dublin (UCD) in advancing their research into non-invasive Continuous Glucose Monitoring (CGM) systems. As a result of this collaboration, Innovation will build on previous work with both the IRC and UCD in advancing a non-invasive multi-sensor approach to recording acute changes in the blood glucose levels of individuals living with diabetes.

“We are delighted to advance our research into a non-invasive CGM system,” said Dr Dean Minnock, CEO, Innovation Zed. “We pride ourselves on taking on the complex technological challenges with our sole aim of easing the stresses caused by diabetes, and this project is no different.” The monitoring of glucose fluctuations is a vital aspect for acute control and improved long-term health outcomes, making it a significant component in the daily life of people with diabetes. Currently, commercial Blood Glucose Meters require a finger prick whilst Continuous Glucose Meters require the insertion of a filament underneath the skin, resulting in small wounds that can be the cause of pain and infections. “There is a clear need for alternative options that are non-invasive, painless, discreet and easy to use, and this is a further step in the right direction,” he continued.

Innovation Zed has already brought to market various technologies to support multiple daily injection (MDI) insulin users with add-on technology that automatically collects essential usage data. Available under the “InsulCheck” brand, these technologies are designed to inform insulin pen users of their injection history and trends.

“We have tremendous experience in designing and developing best-in-class, patient-centred products with the desire of leaving no patient behind when it comes to supporting them. Our partnership with SHL Medical has been instrumental in our ability to design, develop and bring to market these solutions,” said Dr Minnock.

Dr Rui Wu has joined this project as the lead researcher and will be bringing extensive subject knowledge and new focus to the project.

“I am delighted to be involved in this project and to be working with Innovation Zed on this fascinating project,” said Dr Wu. Dr Wu has recently completed a postdoctoral research post at UCD and is supported in this project by Prof Madeleine Lowery, Head of Biomedical Engineering at UCD.

“This non-invasive glucometer project is the latest addition to several exciting projects here at Innovation Zed,” said Dr Minnock. “This is also the first of many fascinating announcements we will be making over the next 12 months. Our strategy of bringing cutting-edge diabetes management technologies to a wider audience is advancing strongly, and we are constantly improving on our portfolio of offerings”.


Innovation Zed and SocialDiabetes Announce Global Partnership

Innovation Zed and SocialDiabetes Announce Global Partnership to Improve Health Outcomes for People with Diabetes

Dublin, Ireland, and Barcelona, Spain 15th July 2021

Innovation Zed Ltd., the developer of novel Insulin Pen “InsulCheck CONNECT” add-on device, and SocialDiabetes, a leading diabetes management company, today announced the signing of a global partnership and data integration agreement.

As a result of this new partnership the companies will pursue joint efforts to promote and sell their products as a single integrated system to improve health outcomes for people with diabetes. Innovation Zed is headquartered at NovaUCD, the Centre for New Ventures and Entrepreneurs at University College Dublin. SocialDiabetes is one of the most established Diabetes management software providers who are headquartered in Barcelona, Spain.

Innovation Zed, launched InsulCheck CONNECT, an insulin pen add-on technology which automatically collects essential usage data that informs insulin pen users of their injection history. When paired with the SocialDiabetes management platform via Bluetooth®, both the end-user and physician can record and view behavioural data to improve diabetes management.

Currently, adherence to insulin therapy is one of the most difficult aspects of diabetes treatment. A simple focus on motivating users to increase adherence to their daily injection schedule can potentially improve their long-term glucose control (HbA1c). Such improvements can assist in reducing the likelihood of developing diabetes related complications.

 “Now that our InsulCheck CONNECT technology is integrated with the SocialDiabetes Platform, we can empower existing platform users, and entice new users to adopt this closed data system ecosystem with aims to improve adherence and their diabetes treatment,” said Dr Dean Minnock, CEO, Innovation Zed.

María Jesús Salido, CEO, SocialDiabetes, said,

“This global partnership is yet another cornerstone in our strategy to bring quality diabetes management to a wider audience. Therapy adherence is a serious issue and we are dedicated to making a cumbersome task as easy as it could be. The unique features for insulin pen users in SocialDiabetes are designed to both save time and allow them to do things, otherwise only available to pump users.”

“We believe the option to calculate and set reminders for split extended bolus and the automated processes that a Bluetooth®connected pen allows will be of great benefit to owners of Innovation Zed’s InsulCheck Connect.”


Collaboration with Cubist

Collaboration with Cubist

Dublin, Ireland 10th June 2021

Cubist have recently implemented a Firmware Over The Air (FOTA) solution for Innovation Zed. The project, which was only started in March of 2021, was completed two weeks ahead of schedule and now advances to manufacturing, test and iOS/Android app development. Reflecting on the progress made to-date, Dean Minnock, CEO of Innovation said,

“It has been great working with the entire Cubist team on this project. From the outset, Cubist was extremely supportive in understanding our needs and timelines. Their integrative and dynamic approach made this collaboration very efficient. We highly recommend Cubist and their services.”


Innovation Zed Appoints New CEO

Innovation Zed Appoints New CEO

Dublin, Ireland 3rd April 2020

We are happy are to announce that Innovation Zed has appointed Dean Minnock as the new Chief Executive Officer following the retirement of Former CEO and Co-Founder John Hughes.

Innovation Zed develops a range of smart add-on technologies for injection pens. Recently, Innovation Zed entered into a commercial partnership with diagnostics and preventive medicine company A. Menarini Diagnostics.

Dean was one of the original employees of Innovation Zed and has extensive experience with both operational and commercial functions of the company. Dean holds a PhD degree from University College Dublin’s School of Public Health, Physiotherapy & Sports Science.

John Hughes, the current director, shareholder and co-founder of Innovation Zed, will continue to share his professional knowledge of the market and provide his invaluable support to the company as an Executive Board Director.


Innovation Zed Enters Commercial Agreement with A. Menarini Diagnostics

Innovation Zed and A. Menarini Diagnostics Enter Commercial Agreement for Innovative medical accessory InsulCheck Connect

Dublin, Ireland, and Florence, Italy 28th January 2020

Innovation Zed, developer of novel Insulin Pen “InsulCheck Connect” add-on device, and A.Menarini Diagnostics, a leading diagnostics company, today announced a partnership to commercialize InsulCheck Connect device developed by Innovation Zed.

“We are very pleased with this announcement,” said John Hughes, CEO of Innovation Zed Ltd., “The relationships that A.Menarini Diagnostics has established with patients and healthcare providers in the diabetes community, and their extensive distribution expertise will positively position us to deliver to key international markets.”

The innovative InsulCheck Connect device was specifically chosen to integrate within A.Menarini Diagnostics’ connected diabetes care platform. According to the agreement, the two companies are forming a long-term partnership where A.Menarini Diagnostics will perform sales, marketing, training, and customer support, providing all necessary technical and clinical information for the correct use of the InsulCheck Connect device in regions around the globe including Europe.

“With this innovative product, healthcare providers and patients will have a powerful tool to take under control the blood glucose levels and prevent diabetes complications.” said Fabio Piazzalunga, General Manager and Global Head of A. Menarini Diagnostics. “This agreement is part of our strategy to develop a portfolio of fully integrated innovative products, allowing an enhanced management of diabetes for healthcare providers and an improved quality of life for patients.”

Dean Minnock, Director of Business Development and Third-Party Relationships at Innovation Zed Ltd., reaffirmed the comments above. Dean also stated:

“A. Menarini Diagnostics has established fantastic relationships with patients and healthcare providers and has extensive distribution expertise to effectively utilise InsulCheck Connect to greatly empower the diabetes community.”

In addition, A. Menarini Diagnostics. and Innovation Zed, Ltd. are discussing terms to commercialize additional innovative systems to improve the quality of life for patients with diabetes.


Innovation Zed and SIRMA Medical Systems Announce Global Partnership

Innovation Zed and SIRMA Medical Systems Announce Global Partnership to Improve Health Outcomes for People with Diabetes

Dublin, Ireland, 18th July 2019

Innovation Zed, an Irish medtech company, today announced the signing of a global partnership and data integration agreement with SIRMA Medical Systems.

As a result of this new partnership the companies will pursue joint efforts to promote and sell their products as a single integrated system to improve health outcomes for people with diabetes.

Innovation Zed, headquartered at NovaUCD, the Centre for New Ventures and Entrepreneurs at University College Dublin, was co-founded by William Cirillo and John Hughes. SIRMA Medical Systems is a division of SIRMA Group, one of the largest privately-owned Bulgarian IT Groups.

Last year Innovation Zed, launched InsulCheck Connect, an insulin pen add-on technology which automatically collects essential usage data that informs insulin pen users of their injection history. When paired with a Bluetooth® enabled device, the end-user can view behavioural analysis on their choice of diabetes management applications.

SIRMA Medical Systems is a leading company in software applications and integrated platforms for e-Health. Its mobile application Diabetes:M is among the most popular applications for both Android and iOS devices, with more than 350,000 installations and 50,000+ active users.

Currently, adherence to insulin therapy is one of the most difficult aspects of diabetes treatment. A simple focus on motivating users to increase adherence to their daily injection schedule can potentially improve their long-term glucose control (HbA1c). Such improvements can assist in reducing the likelihood of developing diabetes related complications.

“Now that our InsulCheck Connect technology is incorporated with the Diabetes:M platform, we can empower existing platform users, and entice new users to adopt this technology ecosystem with aims to improve adherence and their diabetes treatment,” said Dean Minnock, Director of Business Development, Innovation Zed.

“Our products are designed to enable and drive those improvements and combining an advanced data management system such as Diabetes:M platform makes reaching optimum therapy attainable.”

Rossen Varbanov, CEO, SIRMA Medical Systems, said,

“This global partnership is yet another cornerstone in our strategy to bring quality diabetes management to a wider audience. Therapy adherence is a serious issue and we are dedicated to making a cumbersome task as easy as it could be. The unique features for insulin pen users in Diabetes:M are designed to both save time and allow them to do things, otherwise only available to pump users.”

“We believe the option to calculate and set reminders for split extended bolus and the automated processes that a Bluetooth® connected pen allows will be of great benefit to owners of Innovation Zed’s InsulCheck Connect.”

Innovation Zed is an Enterprise Ireland high-potential start-up (HPSU) company.


Innovation Zed and GlucoRX Join Forces

Innovation Zed and GlucoRX join forces to Improve Health Outcomes for People with Diabetes

Dublin, Ireland, 2 May 2018

Innovation Zed, an Irish medtech company, today announced the signing of a global partnership and data integration agreement for its family of insulin pen ‘add-on’ devices with UK-based GlucoRx.

GlucoRx is a leading supplier of innovative management solutions for diabetes in the UK, Ireland, Portugal, Bulgaria, USA, Brazil, Ghana and Kenya.

Innovation Zed, headquartered at NovaUCD, the Centre for New Ventures and Entrepreneurs at University College Dublin (UCD), is dedicated to helping insulin pen users within the diabetes population.

Currently, insulin adherence levels are reported to be around 63% and Innovation Zed’s own research highlights that injection compliance is significantly below what is prescribed.

Studies also demonstrate that a simple focus on motivating users to increase adherence to their daily injection schedule can improve their long-term glucose control (HbA1c) readings. Such improvements can assist in reducing the likelihood of developing diabetes-related complications.

As a result of this new partnership agreement, GlucoRx will immediately begin distributing Innovation Zed’s InsulCheck Classic device, which shows the time since last injection to help people avoid double and missed injections and to help improve HbA1c readings.

“There are tangible health and cost benefits to a 1% improvement in HbA1c,” said John Hughes, CEO, Innovation Zed, himself an insulin user. “Every step towards optimum therapy treatment shows a measurable improvement in the short and long-term health outcomes for patients. Our products are designed to enable and drive those improvements.”

Chris Chapman, Group Managing Director of GlucoRx Ltd, said, “We are confident that thousands of people with diabetes currently on insulin and people needing other injectables will find InsulCheck Classic extremely useful.  GlucoRx is very excited about the healthy pipeline of products that Innovation Zed will be launching in the near future and is looking forward to marketing them in the UK and further afield.”

Innovation Zed’s pipeline includes InsulCheck Connect which the company plans to launch in Q3 2018. InsulCheck Connect automatically collects essential usage data that enables insulin pen users to manage their condition more accurately and more effectively. When paired with a Bluetooth® enabled device, the end-user can view behavioural analysis on their choice of diabetes management applications.

Innovation Zed, an Enterprise Ireland high-potential start-up (HPSU), was co-founded in 2009 by William Cirillo and John Hughes.


Irish Medtech Company Commences Work with the NHS in England

Irish Medtech Company Innovation Zed Commences Work with the NHS in England

Dublin, Ireland, 24th August 2017

Innovation Zed, an Irish medtech company, today announced that it has commenced working with the NHS in South Yorkshire and Bassetlaw, England.

The collaboration sees the company’s novel insulin pen accessory used with diabetes patients as part of a national NHS Test Bed programme exploring new models of care.

InsulCheck Connect, a snap-on accessory for disposable insulin pen users, automatically collects and records pen usage and behaviour data ‘on the go’.

The South Yorkshire and Bassetlaw Perfect Patient Pathway Test Bed is one of 7 national Test Bed programmes in England, funded by NHS England to look at new ways of delivering care for patients by working with technology partners.

The InsulCheck Connect device is being offered to diabetic patients at the Northern General Hospital, Sheffield as part of a programme designed to better support them to manage their condition. It is hoped the programme will involve up to 300 diabetes patients in total.

The expectation is that the data collected by InsulCheck Connect, when merged with other data such as sugar level readings, and as part of a new package of support for diabetic patients, will enable them and their medical professionals to improve the management of the condition and generate better health outcomes.

Once the new care models that are being looked at through the Test Bed programme are evaluated, any models and technology that is seen as successfully supporting patients to improve their care could be made available for other parts of the UK to adopt and adapt to the particular needs of their local populations.

Innovation Zed, headquartered at NovaUCD, the Centre for New Ventures and Entrepreneurs at University College Dublin (UCD), was co-founded in 2009 by John Hughes and William Cirillo.

John Hughes, CEO, Innovation Zed, himself an insulin user, said, “I am delighted to have InsulCheck Connect incorporated in the Perfect Patient Pathway Test Bed programme in South Yorkshire and Bassetlaw.” He added, “Our research with insulin pen users highlights that, as with other conditions, injection compliance is significantly below what is prescribed. We firmly believe that this work will demonstrate that our insulin pen accessory can greatly improve injection compliance and generate better health outcomes for people with diabetes.”

Liz Howarth, South Yorkshire and Bassetlaw Perfect Patient Pathway Test Bed Programme Director said,

“The Test Bed programme is in place to see whether NHS patients can benefit from using new ways of delivering care, combined with new technologies. It’s very early days but we are looking forward to working with our partners, patients and the evaluation team to assess the impact of this particular project.”

Innovation Zed has been dedicated to pro-actively championing the cause of insulin pen users through academic research, scientific studies, clinical trials and developing innovative products.

InsulCheck Connect is the second in a family of connected products from Innovation Zed. It builds on the company’s popular InsulCheck Classic accessory and is the direct result of an intensive four-year research and development project in University College Dublin, Sweden and Taiwan.

John Hughes concluded, “We have already had significant interest in this family of low-cost, insulin pen add-on from private and national health insurance organisations globally as they seek to improve patient outcomes.”


Innovation Zed Announces Novel Insulin Pen Accessory to Improve Diabetes Management

Innovation Zed Announces Novel Insulin Pen Accessory to Improve Diabetes Management

17 October 2016, Dublin, Ireland

Innovation Zed, an established Irish medtech company, has announced a new add-on accessory for insulin pens to enable more flexible insulin management options for people with diabetes.

InsulCheck Connect automatically collects and records insulin pen usage and behaviour data ‘on the go’. This enables new and more flexible therapies to improve diabetes management and to generate better health outcomes. InsulCheck Connect is the latest addition to the company’s InsulCheck Platform, a range of intelligent add-ons to assist insulin pen users.

The company made the announcement and performed demonstrations at the 2016 PDA Universe of Pre-Filled Syringes & Injection Devices conference held in Huntington Beach, California.

John Hughes, CEO at Innovation Zed – and himself an insulin user – explained, “This platform will result in a considerable step up in the performance and effectiveness for the 100+ million existing insulin pen users, enabling functions similar to pump technologies but at a significantly lower cost.”

“We are delighted to be announcing this important development at an event where so many experts in the field are gathered” he added.

Innovation Zed Ltd operates its Research and Development facility at NovaUCD, the Centre for New Ventures and Entrepreneurs at University College Dublin, Ireland and was co-founded by John Hughes and William Cirillo.

Since 2009 the company has been dedicated to pro-actively championing the cause of insulin pen users through academic research, scientific studies, clinical trials and developing innovative products.

InsulCheck Connect builds on the company’s popular InsulCheck Classic accessory and is the direct result of an intensive three-year research and development project.

“Our research with the insulin pen user population, which represents well over 70% of insulin administration today, shows that compliance is significantly below what is prescribed. We firmly believe there are ways to improve this and generate better health outcomes for people with diabetes,” said Technical Director, William Cirillo.

“What was lacking previously was the automatic collection of evidenced behaviour data to enable precise management of the condition. But through InsulCheck Connect that is now here”, he continued.

Innovation Zed is already working with global pharmaceutical companies and diabetes management software providers in an effort to further integrate this valuable data into their products and services.